- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00731796
Testing of a Functional Outcome Measure for Those With Visual Field Defects (FOM)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study will be conducted over 18 months and will be conducted in two phases:
Phase 1 In the first phase, we will determine the validity and reliability of Functional Outcome Measure by applying the Functional Outcome Measure to 20 subjects with homonymous visual field defects (VFD) due to a stoke, 20 stroke cases without visual field defects and 20 normal individuals. They will be asked to perform the Functional Outcome Measure a second time within the following 1-2 weeks in order to evaluate test-retest reliability. The expectation is that those without VFD (stroke and normal individuals) will have good or excellent results on the Functional Outcome Measure, while those with VFD will have abnormal results, thus reflecting the ability of this instrument to record the impairment present in those with VFD. In addition, it is anticipated that the results will be similar after retesting, ensuring test-retest reliability. An interim analysis will determine if the instrument is valid and if all its components correlate with the magnitude of visual field loss (as measured by High Resolution perimetry). Once the validation of the instrument has been accomplished, the functional outcome measure will be amended as suggested by this analysis to include only the items that correlate well with VFD.
The functional outcome measure will be administered either at the NovaVision, Inc. office (normal individuals) or in cooperating medical centers (stroke patients with or without visual field defect).
Phase 2 In the second phase, the amended version of the Functional Outcome Instrument will be administered to individuals with VFD. Two groups will be studied: 100 cases which will perform Vision Restoration Therapy (VRT), and 50 controls that will not. The latter group will include the 20 patients with VFD studied in Phase 1. Both groups will undergo visual field testing with high resolution perimetry, and will complete the Functional Outcome Measure on 4 occasions: twice within a 2 week interval at baseline, once after three months, and once after 6-7 months, with one of the groups having completed therapy during this time.
Visual field testing (high resolution perimetry) will be administered at cooperating medical centers. While patients undergoing VRT will perform the functional outcome measure once at the center and once on their VRT device at home, controls will perform their functional outcome measure at the medical center only, as they don't have access to a VRT device at home.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
Florida
-
Boca Raton, Florida, United States, 33431
- NovaVision, Inc.
-
Miami, Florida, United States, 33136
- University of Miami Bascom Palmer
-
-
Georgia
-
Atlanta, Georgia, United States, 30332
- Emory University School of Medicine Atlanta VA Medical Center Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Stroke victim
- Read / Speak English (required to respond to the questionaire)
- Ability to provide consent
- Homonymous visual field defect evident on a suprathreshold visual field test (High Resolution Perimetry)
- 18 years fo age and older
Exclusion Criteria:
- Contraindication to visual stimulation: history of photogenic seizures
- Inability to complete Vision Restoration Therapy
- Significant cognitive impairment
- Complete blindness or the inability to focus on a fixation point
- Severe physical or behavioral limitations
- Aphasia
- Onset of Visual field defect less than 3 months prior to enrollment
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
1
Stroke victims with a visual field deficit that undergo vision restoration therapy
|
Functional Outcome Measure is a computerized test performed by the subject.
The subject sits at a computer and answers questions about their visual deficit and its impact.
The patient then performs a Vision Preference Scale test intended to rate the overall quality of life.
A reading test is performed that measures reading speed, accuracy, and comprehension.
Finally a Visuospatial Attention test is given to measure object localization, object recognition,and motion recognition.
|
2
Stroke victims with a visual field deficit who do not undergo any rehabilitation intervention
|
Functional Outcome Measure is a computerized test performed by the subject.
The subject sits at a computer and answers questions about their visual deficit and its impact.
The patient then performs a Vision Preference Scale test intended to rate the overall quality of life.
A reading test is performed that measures reading speed, accuracy, and comprehension.
Finally a Visuospatial Attention test is given to measure object localization, object recognition,and motion recognition.
|
3
Stroke victims that do not have a visual field deficit
|
Functional Outcome Measure is a computerized test performed by the subject.
The subject sits at a computer and answers questions about their visual deficit and its impact.
The patient then performs a Vision Preference Scale test intended to rate the overall quality of life.
A reading test is performed that measures reading speed, accuracy, and comprehension.
Finally a Visuospatial Attention test is given to measure object localization, object recognition,and motion recognition.
|
4
Normal individuals who have not had a stroke and do not have a visual field deficit
|
Functional Outcome Measure is a computerized test performed by the subject.
The subject sits at a computer and answers questions about their visual deficit and its impact.
The patient then performs a Vision Preference Scale test intended to rate the overall quality of life.
A reading test is performed that measures reading speed, accuracy, and comprehension.
Finally a Visuospatial Attention test is given to measure object localization, object recognition,and motion recognition.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Determine the ability of a Functional Outcome Measure to distinguish visual impairment in those with retrochiasmatic insults and visual field defects compared to those without visual field defects
Time Frame: 18 Months
|
18 Months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Identify the correlation between the degree of functional impairment and the amount of visual field loss
Time Frame: 18 months
|
18 months
|
Determine the ability of a Functional Outcome Measure to detect change after a rehabilitation intervention
Time Frame: 18 months
|
18 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Sigrid Kenkel, NovaVision, Inc.
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NUSRPFOM01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hemianopsia, Homonymous
-
Wake Forest University Health SciencesCompletedHemianopia, Homonymous | Hemianopsia, HomonymousUnited States
-
Nunaps IncCompletedVisual Fields Hemianopsia | Hemianopsia, HomonymousKorea, Republic of
-
Massachusetts Eye and Ear InfirmaryNational Eye Institute (NEI)Not yet recruitingHomonymous Hemianopia | Homonymous QuadrantanopiaUnited States
-
Nunaps IncActive, not recruitingVisual Fields Hemianopsia | Hemianopsia, HomonymousKorea, Republic of
-
Alexandra BowersNational Eye Institute (NEI); Chadwick Optical Inc.CompletedHomonymous HemianopiaUnited States, United Kingdom
-
Institute of Child HealthEnrolling by invitation
-
Massachusetts Eye and Ear InfirmaryNational Eye Institute (NEI)Recruiting
-
University of RochesterNational Institutes of Health (NIH)RecruitingStroke, Ischemic | Stroke Hemorrhagic | Visual Field Defect, Peripheral | Hemianopsia | Hemianopia | Quadrantanopia | Homonymous Hemianopia | Occipital Lobe Infarct | Visual Fields Hemianopsia | Vision Loss Partial | Peripheral Visual Field Defect of Both Eyes | Peripheral Visual Field Defect | Homonymous Hemianopsia and other conditionsUnited States
-
University of RochesterRochester Institute of TechnologyRecruitingStroke, Ischemic | Stroke Hemorrhagic | Hemianopia, Homonymous | Visual Field Defect, Peripheral | Hemianopsia | Hemianopia | Quadrantanopia | Occipital Lobe Infarct | Hemianopsia, Homonymous | Vision Loss Partial | QuadrantanopsiaUnited States
-
Massachusetts Eye and Ear InfirmaryNational Eye Institute (NEI)RecruitingHemianopia, Homonymous | Tunnel Vision | Visual Field Defect, Peripheral | Visual Field Constriction Bilateral | Visual Field Defect Homonymous BilateralUnited States
Clinical Trials on Functional Outcome Measure
-
Universidade Nova de LisboaiNOVA4Health, NOVA Medical School|Faculdade de Ciências Médicas, NMS|FCM,... and other collaboratorsRecruitingAge-Related Macular DegenerationPortugal
-
Karolinska InstitutetSkandinaviska Forskningsstiftelsen för Åderbråck och andra VensjukdomarCompletedQuality of Life | Superficial Venous Insufficiency | Change After TreatmentSweden
-
Izmir Katip Celebi UniversityUnknown
-
Universidade Nova de LisboaUniversity of Évora; NOVA Medical School | Faculdade de Ciências Médicas, Universidade... and other collaboratorsNot yet recruiting
-
University Hospital HeidelbergHealth Economics and Health Care Management, Bielefeld University; Chair of... and other collaboratorsCompleted
-
University of Colorado, DenverNational Cancer Institute (NCI)RecruitingBreast CancerUnited States
-
Universidade Estadual do Oeste do ParanáCompletedIntensive Care (ICU) Myopathy | Functional Independence
-
Beijing Neurosurgical InstituteRecruitingCerebral Hemorrhage | Artificial Intelligence | PrognosisChina
-
University of BernCompletedEmotional Stress | EmbittermentSwitzerland
-
University of TennesseeAstraZeneca; Vanderbilt University Medical CenterRecruitingMultiple Myeloma | Chronic Lymphocytic Leukemia | Chronic Myeloid Leukemia | Multiple Chronic ConditionsUnited States